Top Markets
#1 OSK OSK +15.48%
#2 Ardor Ardor +7.80%
#3 MarsCoin MarsCoin +7.36%
#4 Tornado Cash Tornado Cash +6.57%
#5 HOME HOME +5.86%
#6 UnifAI Network UnifAI Network +4.33%
#7 AI XOVIA AI XOVIA +4.25%
#8 Story Story +4.12%
#9 Cash Cat Cash Cat +3.55%
#10 Anvil Anvil +2.93%
Coin of the day
OSK OSK
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Adagio Therapeutics, Inc. Adagio Therapeutics, Inc.

Adagio Therapeutics, Inc.

ADGI
Classifica tra le azioni #16435
Adagio Therapeutics, Inc. is a clinical-stage biopharmaceutical firm, primarily... Adagio Therapeutics, Inc. is a clinical-stage biopharmaceutical firm, primarily focused on the discovery, development, and subsequent commercialization of antibody-based therapeutics designed to combat infectious diseases across the United States. Its most advanced product candidate, ADG20 (adintrevimab), is a neutralizing antibody currently undergoing Phase 3 clinical trials. This antibody is being evaluated for both the treatment and prevention of coronavirus disease. Adagio Therapeutics also engages in strategic collaborations. It partners with Adimab, LLC to facilitate the discovery and optimization of novel proprietary antibodies. Furthermore, the company works with the Scripps Research Institute on research initiatives aimed at identifying vaccine candidates that could prevent, diagnose, or treat influenza and beta coronaviruses. Founded in 2020, Adagio Therapeutics maintains its headquarters in Waltham, Massachusetts.
Prezzo delle azioni
$4.64
Ultima sincronizzazione: 2022-09-12
Capitalizzazione di mercato
$293.43M
Variazione (1 giorno)
0.87%
Variazione (1 anno)
0.00%
Paese
US
Scambia Adagio Therapeutics, Inc. (ADGI)

Categoria

Healthcare
Ricavi di Adagio Therapeutics, Inc. (ADGI)
Ricavi nel Sep 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Adagio Therapeutics, Inc., i ricavi attuali dell'azienda (TTM) sono pari a 0. Nel 2026, l'azienda ha registrato ricavi di 0 uguale a i ricavi dell'anno 2026, che erano pari a 0. I ricavi rappresentano l'importo totale generato dalla vendita di beni o servizi. A differenza degli utili, le spese non vengono detratte.
Storico dei ricavi per Adagio Therapeutics, Inc. da 2026 a 2026
Ricavi alla fine di ogni anno
Anno Ricavi Cambia
Non abbastanza dati per le date fornite.
Ricavi di aziende simili o concorrenti
Azienda Ricavi Differenza nei ricavi Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH